• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azobenzenes

Recent Advances in the Study of N-5-Bis(2-methoxyethyl)amino-2-(2-cyano-4-nitrophenyl)azophenylacetamide (CAS: 52549-57-2)

In recent years, the compound N-5-Bis(2-methoxyethyl)amino-2-(2-cyano-4-nitrophenyl)azophenylacetamide (CAS: 52549-57-2) has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, has shown promising potential in various therapeutic applications. The following research brief synthesizes the latest findings related to this compound, focusing on its synthesis, mechanism of action, and potential clinical applications.

The synthesis of N-5-Bis(2-methoxyethyl)amino-2-(2-cyano-4-nitrophenyl)azophenylacetamide involves a multi-step process that has been optimized in recent studies to improve yield and purity. Advanced spectroscopic techniques, including NMR and mass spectrometry, have been employed to confirm the structural integrity of the compound. Researchers have also explored its stability under various physiological conditions, which is critical for its potential use as a drug candidate.

Mechanistic studies have revealed that this compound exhibits a high affinity for specific biological targets, particularly enzymes involved in inflammatory pathways. In vitro assays have demonstrated its inhibitory effects on key inflammatory mediators, suggesting its potential as an anti-inflammatory agent. Furthermore, molecular docking simulations have provided insights into the binding interactions between the compound and its target proteins, highlighting the importance of its nitro and cyano functional groups in these interactions.

Recent preclinical studies have evaluated the pharmacokinetic and pharmacodynamic properties of N-5-Bis(2-methoxyethyl)amino-2-(2-cyano-4-nitrophenyl)azophenylacetamide. These studies have shown favorable absorption and distribution profiles, with minimal toxicity observed in animal models. The compound's ability to cross the blood-brain barrier has also been investigated, opening up possibilities for its use in treating neurological disorders.

Despite these promising findings, challenges remain in the development of this compound for clinical use. Issues such as metabolic stability and potential off-target effects need to be addressed in future research. However, the current body of work underscores the therapeutic potential of N-5-Bis(2-methoxyethyl)amino-2-(2-cyano-4-nitrophenyl)azophenylacetamide and provides a solid foundation for further investigation.

In conclusion, the latest research on N-5-Bis(2-methoxyethyl)amino-2-(2-cyano-4-nitrophenyl)azophenylacetamide (CAS: 52549-57-2) highlights its potential as a novel therapeutic agent. Continued efforts to optimize its synthesis, elucidate its mechanism of action, and evaluate its safety and efficacy will be crucial in advancing this compound toward clinical applications.

• 41642-51-7(Disperse Blue 165)
• 77538-14-8(Disperse Violet 77)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)